BANK1 | B-cell scaffold protein with ankyrin repeats 1 | Disease related genes
| | | | | Tissue enhanced |
BATF | Basic leucine zipper transcription factor, ATF-like | Transcription factors
| | | | | Tissue enhanced |
BCL2A1 | BCL2-related protein A1 | Cancer-related genes
| | | | | Tissue enhanced |
BFSP2 | Beaded filament structural protein 2, phakinin | Disease related genes
| | | | | Tissue enhanced |
BLK | B lymphoid tyrosine kinase | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Group enriched |
BPI | Bactericidal/permeability-increasing protein | Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
BST1 | Bone marrow stromal cell antigen 1 | CD markers Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
BTLA | B and T lymphocyte associated | CD markers Predicted membrane proteins
| | | | | Group enriched |
C10orf105 | Chromosome 10 open reading frame 105 | | | | | | Tissue enhanced |
C11orf21 | Chromosome 11 open reading frame 21 | | | | | | Tissue enhanced |
C12orf77 | Chromosome 12 open reading frame 77 | | | | | | Group enriched |
C12orf79 | Chromosome 12 open reading frame 79 | | | | | | Tissue enriched |
C15ORF31 | | Predicted secreted proteins
| | | | | Tissue enriched |
C16orf54 | Chromosome 16 open reading frame 54 | Predicted membrane proteins
| | | | | Tissue enhanced |
C17orf53 | Chromosome 17 open reading frame 53 | | | | | | Tissue enhanced |
C17orf99 | Chromosome 17 open reading frame 99 | Predicted secreted proteins
| | | | | Tissue enriched |
C19orf35 | Chromosome 19 open reading frame 35 | | | | | | Tissue enhanced |
C19orf38 | Chromosome 19 open reading frame 38 | Predicted membrane proteins
| | | | | Tissue enhanced |
C19orf59 | Chromosome 19 open reading frame 59 | Predicted membrane proteins
| | | | | Group enriched |
C1orf228 | Chromosome 1 open reading frame 228 | | | | | | Tissue enhanced |
C1QTNF1-AS1 | C1QTNF1 antisense RNA 1 | | | | | | Tissue enhanced |
C21orf90 | Chromosome 21 open reading frame 90 | | | | | | Tissue enhanced |
C2orf48 | Chromosome 2 open reading frame 48 | | | | | | Tissue enhanced |
C5AR2 | Complement component 5a receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
C5orf66 | Chromosome 5 open reading frame 66 | | | | | | Tissue enhanced |
C9orf139 | Chromosome 9 open reading frame 139 | | | | | | Tissue enhanced |
CA1 | Carbonic anhydrase I | Enzymes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
CABP4 | Calcium binding protein 4 | Disease related genes
| | | | | Tissue enhanced |
CAMP | Cathelicidin antimicrobial peptide | Plasma proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
CARD11 | Caspase recruitment domain family, member 11 | Cancer-related genes Disease related genes
| | | | | Tissue enhanced |
CARD9 | Caspase recruitment domain family, member 9 | Disease related genes
| | | | | Tissue enhanced |
CASP16 | Caspase 16, apoptosis-related cysteine peptidase (putative) | Enzymes
| | | | | Group enriched |
CASP5 | Caspase 5, apoptosis-related cysteine peptidase | Cancer-related genes Enzymes Plasma proteins
| | | | | Group enriched |
CASS4 | Cas scaffolding protein family member 4 | Cytoskeleton related proteins Plasma proteins
| | | | | Tissue enhanced |
CBX4 | Chromobox homolog 4 | | | | | | Tissue enhanced |
CCL14 | Chemokine (C-C motif) ligand 14 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCL17 | Chemokine (C-C motif) ligand 17 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL19 | Chemokine (C-C motif) ligand 19 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CCL21 | Chemokine (C-C motif) ligand 21 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCL22 | Chemokine (C-C motif) ligand 22 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL3 | Chemokine (C-C motif) ligand 3 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CCL3L1 | Chemokine (C-C motif) ligand 3-like 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL3L3 | Chemokine (C-C motif) ligand 3-like 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL4 | Chemokine (C-C motif) ligand 4 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CCL4L1 | Chemokine (C-C motif) ligand 4-like 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL4L2 | Chemokine (C-C motif) ligand 4-like 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL7 | Chemokine (C-C motif) ligand 7 | Cancer-related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
CCM2L | Cerebral cavernous malformation 2-like | Plasma proteins
| | | | | Tissue enriched |
CCNE1 | Cyclin E1 | Cancer-related genes
| | | | | Tissue enhanced |